Production (Stage)
Evoke Pharma, Inc.
EVOK
$2.89
-$0.0574-1.95%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -6.90% | 24.65% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -6.90% | 24.65% | |||
| Cost of Revenue | -64.89% | 13.94% | |||
| Gross Profit | -4.75% | 25.08% | |||
| SG&A Expenses | -1.96% | 14.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.67% | 14.27% | |||
| Operating Income | -9.05% | 7.16% | |||
| Income Before Tax | -9.51% | 9.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.51% | 9.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.51% | 9.11% | |||
| EBIT | -9.05% | 7.16% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -49.33% | 63.39% | |||
| Normalized Basic EPS | -49.32% | 63.39% | |||
| EPS Diluted | -49.33% | 63.39% | |||
| Normalized Diluted EPS | -49.32% | 63.39% | |||
| Average Basic Shares Outstanding | -26.66% | 148.25% | |||
| Average Diluted Shares Outstanding | -26.66% | 148.25% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||